deltatrials
Unknown PHASE3 INTERVENTIONAL 1-arm NCT03635580

Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS

Phase 2 Study of Efficacy and Safety of rhGH (Jintropin®) in Pediatric Participants With ISS (Idiopathic Short Stature): a 52-week Multicenter, Open-label, Randomized, Negative Controlled Study Followed by a 52-week Open-label Period

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Conditions Dwarfism
Interventions Negative control
Updated 13 times since 2018 Last updated: Aug 15, 2018 Started: Jun 11, 2018 Primary completion: Oct 31, 2021 Completion: Oct 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Dwarfism and is currently ongoing. Changchun GeneScience Pharmaceutical Co., Ltd. leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Apr 2020 · 15 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Sep 2023 · 18 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Oct 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

  5. Sep 2023 — Oct 2023 [monthly]

    Unknown Status PHASE3

▶ Show 8 earlier versions

  1. Mar 2022 — Sep 2023 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  2. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

  3. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  4. Apr 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  5. Jan 2019 — Apr 2020 [monthly]

    Recruiting PHASE3

  6. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  7. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  8. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Changchun GeneScience Pharmaceutical Co., Ltd.
  • Children's Hospital of Fudan University
  • First Affiliated Hospital, Sun Yat-Sen University
  • Henan Provincial People's Hospital
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Shanghai Children's Hospital
  • Shanxi Provincial Maternity and Children's Hospital
  • The Children's Hospital of Zhejiang University School of Medicine
  • The First Affiliated Hospital with Nanjing Medical University
  • The First Hospital of Jilin University
Data source: Changchun GeneScience Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations